The cation channel Trpv2 is a new suppressor of arthritis severity, joint damage, and synovial fibroblast invasion

Clinical Immunology

Volumn 158, Issue 2, 2015, Pages 183-192

  Laragione, Teresina ^a   Cheng, Kai F ^b   Tanner, Mark R ^c   He, Mingzhu ^b   Beeton, Christine ^c   Al Abed, Yousef ^b   Gulko, Pércio S ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Angiogenesis; Arthritis; Autoimmunity; Ion channels; Pathogenesis; Synovitis

Indexed keywords

CALCIUM; GELATINASE A; INTERLEUKIN 1BETA; STROMELYSIN; VANILLOID RECEPTOR 2; CALCIUM CHANNEL; CANNABIDIOL; CANNABINOID; COLLAGEN; O-1821 COMPOUND; PRISTANE; SMALL INTERFERING RNA; TERPENE; TRPV2 PROTEIN, HUMAN; TRPV2 PROTEIN, MOUSE; TRPV2 PROTEIN, RAT; VANILLOID RECEPTOR;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTHRITIS; ARTICLE; CALCIUM CELL LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG POTENCY; FIBROBLAST; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; JOINT INJURY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RHEUMATOID ARTHRITIS; SYNOVITIS; SYNOVIUM; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; CHEMICALLY INDUCED; CYTOLOGY; DRUG EFFECTS; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; RNA INTERFERENCE; TISSUE CULTURE TECHNIQUE;

ANIMALS; ARTHRITIS; ARTHRITIS, RHEUMATOID; CALCIUM CHANNELS; CANNABIDIOL; CANNABINOIDS; COLLAGEN; FIBROBLASTS; HUMANS; MICE; RATS; RNA INTERFERENCE; RNA, SMALL INTERFERING; SYNOVIAL MEMBRANE; TERPENES; TISSUE CULTURE TECHNIQUES; TRPV CATION CHANNELS;

EID: 84928609702     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2015.04.001     Document Type: Article

References (47)

1. Simonsson M., Bergman S., Jacobsson L.T., Petersson I.F., Svensson B. The prevalence of rheumatoid arthritis in Sweden. Scand. J. Rheumatol. 1999, 28(6):340-343.
2. van Zeben D., Breedveld F.C. Prognostic factors in rheumatoid arthritis. J. Rheumatol. Suppl. 1996, 44:31-33.
3. Gossec L., Dougados M., Goupille P., Cantagrel A., Sibilia J., Meyer O., Sany J., Daures J.P., Combe B. Prognostic factors for remission in early rheumatoid arthritis: a multiparameter prospective study. Ann. Rheum. Dis. 2004, 63(6):675-680.
4. Wolfe F., Mitchell D.M., Sibley J.T., Fries J.F., Bloch D.A., Williams C.A., Spitz P.W., Haga M., Kleinheksel S.M., Cathey M.A. The mortality of rheumatoid arthritis. Arthritis Rheum. 1994, 37(4):481-494.
5. Bartok B., Firestein G.S. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol. Rev. 2010, 233(1):233-255.
6. Tolboom T.C., van der Helm-Van Mil A.H., Nelissen R.G., Breedveld F.C., Toes R.E., Huizinga T.W. Invasiveness of fibroblast-like synoviocytes is an individual patient characteristic associated with the rate of joint destruction in patients with rheumatoid arthritis. Arthritis Rheum. 2005, 52(7):1999-2002.
7. Laragione T., Brenner M., Mello A., Symons M., Gulko P.S. The arthritis severity locus Cia5d is a novel genetic regulator of the invasive properties of synovial fibroblasts. Arthritis Rheum. 2008, 58(8):2296-2306.
8. Laragione T., Gulko P.S. mTOR regulates the invasive properties of synovial fibroblasts in rheumatoid arthritis. Mol. Med. 2010, 16(9-10):352-358.
9. Gulko P.S. Contribution of genetic studies in rodent models of autoimmune arthritis to understanding and treatment of rheumatoid arthritis. Genes Immun. 2007, 8(7):523-531.
10. Laragione T., Brenner M., Li W., Gulko P.S. Cia5d regulates a new fibroblast-like synoviocyte invasion-associated gene expression signature. Arthritis Res. Ther. 2008, 10(4):R92.
11. Engler A., Aeschlimann A., Simmen B.R., Michel B.A., Gay R.E., Gay S., Sprott H. Expression of transient receptor potential vanilloid 1 (TRPV1) in synovial fibroblasts from patients with osteoarthritis and rheumatoid arthritis. Biochem. Biophys. Res. Commun. 2007, 359(4):884-888.
12. Kochukov M.Y., McNearney T.A., Fu Y., Westlund K.N. Thermosensitive TRP ion channels mediate cytosolic calcium response in human synoviocytes. Am. J. Physiol. Cell Physiol. 2006, 291(3):C424-C432.
13. Ciurtin C., Majeed Y., Naylor J., Sukumar P., English A.A., Emery P., Beech D.J. TRPM3 channel stimulated by pregnenolone sulphate in synovial fibroblasts and negatively coupled to hyaluronan. BMC Musculoskelet. Disord. 2010, 11:111.
14. Xu S.Z., Sukumar P., Zeng F., Li J., Jairaman A., English A., Naylor J., Ciurtin C., Majeed Y., Milligan C.J., et al. TRPC channel activation by extracellular thioredoxin. Nature 2008, 451(7174):69-72.
15. Caterina M.J., Rosen T.A., Tominaga M., Brake A.J., Julius D. A capsaicin-receptor homologue with a high threshold for noxious heat. Nature 1999, 398(6726):436-441.
16. Link T.M., Park U., Vonakis B.M., Raben D.M., Soloski M.J., Caterina M.J. TRPV2 has a pivotal role in macrophage particle binding and phagocytosis. Nat. Immunol. 2010, 11(3):232-239.
17. Vingsbo C., Sahlstrand P., Brun J.G., Jonsson R., Saxne T., Holmdahl R. Pristane-induced arthritis in rats: a new model for rheumatoid arthritis with a chronic disease course influenced by both major histocompatibility complex and non-major histocompatibility complex genes. Am. J. Pathol. 1996, 149(5):1675-1683.
18. Brenner M., Meng H., Yarlett N., Griffiths M., Remmers E., Wilder R., Gulko P. The non-MHC quantitative trait locus Cia10 contains a major arthritis gene and regulates disease severity, pannus formation, and joint damage. Arthritis Rheum. 2005, 52(1):322-332.
19. Arnett F.C., Edworthy S.M., Bloch D.A., McShane D.J., Fries J.F., Cooper N.S., Healey L.A., Kaplan S.R., Liang M.H., Luthra H.S., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988, 31(3):315-324.
20. Qin N., Neeper M.P., Liu Y., Hutchinson T.L., Lubin M.L., Flores C.M. TRPV2 is activated by cannabidiol and mediates CGRP release in cultured rat dorsal root ganglion neurons. J. Neurosci. 2008, 28(24):6231-6238.
21. Offertaler L., Mo F.M., Batkai S., Liu J., Begg M., Razdan R.K., Martin B.R., Bukoski R.D., Kunos G. Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor. Mol. Pharmacol. 2003, 63(3):699-705.
22. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25(4):402-408.
23. Laragione T., Brenner M., Sherry B., Gulko P.S. CXCL10 and its receptor CXCR3 regulate synovial fibroblast invasion in rheumatoid arthritis. Arthritis Rheum. 2011, 63(11):3274-3283.
24. Chan A., Akhtar M., Brenner M., Zheng Y., Gulko P.S., Symons M. The GTPase Rac regulates the proliferation and invasion of fibroblast-like synoviocytes from rheumatoid arthritis patients. Mol. Med. 2007, 13(5-6):297-304.
25. Ji H., Gauguier D., Ohmura K., Gonzalez A., Duchatelle V., Danoy P., Garchon H.J., Degott C., Lathrop M., Benoist C., et al. Genetic influences on the end-stage effector phase of arthritis. J. Exp. Med. 2001, 194(3):321-330.
26. Jirholt J., Cook A., Emahazion T., Sundvall M., Jansson L., Nordquist N., Pettersson U., Holmdahl R. Genetic linkage analysis of collagen-induced arthritis in the mouse. Eur. J. Immunol. 1998, 28(10):3321-3328.
27. Courtenay J.S., Dallman M.J., Dayan A.D., Martin A., Mosedale B. Immunisation against heterologous type II collagen induces arthritis in mice. Nature 1980, 283(5748):666-668.
28. Nagler-Anderson C., Bober L.A., Robinson M.E., Siskind G.W., Thorbecke G.J. Suppression of type II collagen-induced arthritis by intragastric administration of soluble type II collagen. Proc. Natl. Acad. Sci. U. S. A. 1986, 83(19):7443-7446.
29. Brenner M., Meng H.C., Yarlett N.C., Joe B., Griffiths M.M., Remmers E.F., Wilder R.L., Gulko P.S. The non-MHC quantitative trait locus Cia5 contains three major arthritis genes that differentially regulate disease severity, pannus formation, and joint damage in collagen- and pristane-induced arthritis. J. Immunol. 2005, 174(12):7894-7903.
30. Mihara H., Boudaka A., Shibasaki K., Yamanaka A., Sugiyama T., Tominaga M. Involvement of TRPV2 activation in intestinal movement through nitric oxide production in mice. J. Neurosci. 2010, 30(49):16536-16544.
31. Iwata Y., Katanosaka Y., Arai Y., Shigekawa M., Wakabayashi S. Dominant-negative inhibition of Ca2+ influx via TRPV2 ameliorates muscular dystrophy in animal models. Hum. Mol. Genet. 2009, 18(5):824-834.
32. Nabissi M., Morelli M.B., Amantini C., Farfariello V., Ricci-Vitiani L., Caprodossi S., Arcella A., Santoni M., Giangaspero F., De Maria R., et al. TRPV2 channel negatively controls glioma cell proliferation and resistance to Fas-induced apoptosis in ERK-dependent manner. Carcinogenesis 2010, 31(5):794-803.
33. McCleverty C.J., Koesema E., Patapoutian A., Lesley S.A., Kreusch A. Crystal structure of the human TRPV2 channel ankyrin repeat domain. Protein Sci. 2006, 15(9):2201-2206.
34. Carlson R.P., Hartman D.A., Tomchek L.A., Walter T.L., Lugay J.R., Calhoun W., Sehgal S.N., Chang J.Y. Rapamycin, a potential disease-modifying antiarthritic drug. J. Pharmacol. Exp. Ther. 1993, 266(2):1125-1138.
35. Mohan K., Issekutz T.B. Blockade of chemokine receptor CXCR3 inhibits T cell recruitment to inflamed joints and decreases the severity of adjuvant arthritis. J. Immunol. 2007, 179(12):8463-8469.
36. Cejka D., Hayer S., Niederreiter B., Sieghart W., Fuereder T., Zwerina J., Schett G. Mammalian target of rapamycin signaling is crucial for joint destruction in experimental arthritis and is activated in osteoclasts from patients with rheumatoid arthritis. Arthritis Rheum. 2010, 62(8):2294-2302.
37. Bruyn G.A., Tate G., Caeiro F., Maldonado-Cocco J., Westhovens R., Tannenbaum H., Bell M., Forre O., Bjorneboe O., Tak P.P., et al. Everolimus in patients with rheumatoid arthritis receiving concomitant methotrexate: a 3-month, double-blind, randomised, placebo-controlled, parallel-group, proof-of-concept study. Ann. Rheum. Dis. 2008, 67(8):1090-1095.
38. Yellin M., Paliienko I., Balanescu A., Ter-Vartanian S., Tseluyko V., Xu L.A., Tao X., Cardarelli P.M., Leblanc H., Nichol G., et al. A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 2012, 64(6):1730-1739.
39. Tobar N., Villar V., Santibanez J.F. ROS-NFkappaB mediates TGF-beta1-induced expression of urokinase-type plasminogen activator, matrix metalloproteinase-9 and cell invasion. Mol. Cell. Biochem. 2010, 340(1-2):195-202.
40. Miagkov A.V., Kovalenko D.V., Brown C.E., Didsbury J.R., Cogswell J.P., Stimpson S.A., Baldwin A.S., Makarov S.S. NF-kappaB activation provides the potential link between inflammation and hyperplasia in the arthritic joint. Proc. Natl. Acad. Sci. U. S. A. 1998, 95(23):13859-13864.
41. Lin M.T., Lin B.R., Chang C.C., Chu C.Y., Su H.J., Chen S.T., Jeng Y.M., Kuo M.L. IL-6 induces AGS gastric cancer cell invasion via activation of the c-Src/RhoA/ROCK signaling pathway. Int. J. Cancer 2007, 120(12):2600-2608.
42. Li H., Huang C., Huang K., Wu W., Jiang T., Cao J., Feng Z., Qiu Z. STAT3 knockdown reduces pancreatic cancer cell invasiveness and matrix metalloproteinase-7 expression in nude mice. PLoS ONE 2011, 6(10). (e25941).
43. Price L.S., Collard J.G. Regulation of the cytoskeleton by Rho-family GTPases: implications for tumour cell invasion. Semin. Cancer Biol. 2001, 11(2):167-173.
44. Stengel K., Zheng Y. Cdc42 in oncogenic transformation, invasion, and tumorigenesis. Cell. Signal. 2011, 23(9):1415-1423.
45. Kikuchi K., Li X., Zheng Y., Takano Y. Invasion of breast cancer cells into collagen matrix requires TGF-alpha and Cdc42 signaling. FEBS Lett. 2011, 585(2):286-290.
46. Friedl P., Alexander S. Cancer invasion and the microenvironment: plasticity and reciprocity. Cell 2011, 147(5):992-1009.
47. Leivonen S.K., Kahari V.M. Transforming growth factor-beta signaling in cancer invasion and metastasis. Int. J. Cancer 2007, 121(10):2119-2124.